Omeros Corp. (OMER), a clinical-stage biopharmaceutical company, Tuesday said it has filed a Clinical Trial Application or CTA with European regulators to initiate clinical trials evaluating OMS721, the company's lead human monoclonal antibody from its mannan-binding lectin-associated serine protease-2 or MASP-2 program.
The lead indication for OMS721 will be atypical hemolytic uremic syndrome, a rare but life-threatening form of thrombotic microangiopathy. Assuming positive regulatory review of its CTA, Omeros plans to initiate a Phase 1 clinical trial evaluating OMS721 early next quarter.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.